Enzalutamide and Quality of Life in Prostate CancerFreedland et al. present the health-related quality of life outcomes for patients with biochemically recurrent prostate cancer who were randomly assigned to enzalutamide plus leuprolide, enzalutamide monotherapy, or leuprolide alone (EMBARK trial).
The key objectives were to determine differences in time to first and confirmed clinically meaningful deterioration in pain and time to first and confirmed clinically meaningful deterioration in functional status. There were no differences among the key outcomes among all three groups.
NEJM evidence. 2023 Oct 22 [Epub]
Stephen J Freedland, Martin Gleave, Ugo De Giorgi, Antti Rannikko, Christopher M Pieczonka, Ronald F Tutrone, Balaji Venugopal, Henry H Woo, Miguel Ramirez-Backhaus, Stephane Supiot, Anna Lantz, Arijit Ganguli, Jasmina Ivanova, Pavol Kral, Shu-Pin Huang, Fred Saad, Neal D Shore
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles., The Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada., IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy., Department of Urology and Research Program in Systems Oncology, University of Helsinki, Helsinki., U.S. Urology Partners and Associated Medical Professionals of New York, Syracuse, NY., Chesapeake Urology Research Associates, Towson, MD., Beatson West of Scotland Cancer Center, University of Glasgow, Glasgow, United Kingdom., SAN Prostate Center of Excellence, Sydney Adventist Hospital, Sydney., Servicio de Urología, Fundación Instituto Valenciano de Oncología, Valencia, Spain., Institut de Cancérologie de l'Ouest, site Rene Gauducheau, Saint-Herblain, France., Karolinska Universitetssjukhuset, Solna, Sweden., Medical Affairs, Astellas Pharma, Northbrook, IL., Pfizer, New York., IQVIA, Bratislava, Slovakia., Department of Urology, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan., Centre Hospitalier de l'Université de Montréal, Montreal., Carolina Urologic Research Center/GenesisCare US, Myrtle Beach, SC.